Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The report details the outcome of a legal investigation into GSK China Investment Co. Ltd (GSKCI) by Chinese authorities, specifically regarding bribery of non-government personnel.
Key Financial Metrics
The filing discloses a specific financial penalty resulting from the court verdict:
- Penalty Fine: £297 million (equivalent to 3 billion RMB at an exchange rate of 10.0980).
- Funding Source: The fine will be funded through existing cash resources.
- Additional Costs: Associated costs and charges related to restructuring will be included in GSK's third-quarter update.
The filing text does not provide clear values for total revenue, profit, cash flow, margins, debt, or overall liquidity for the period.
Material Changes and Unusual Items
The primary material change is the criminal conviction of GSKCI by the Changsha Intermediate People's Court in Hunan Province, China. The court ruled that GSKCI offered money or property to non-government personnel to obtain improper commercial gains. This follows investigations initiated by China's Ministry of Public Security in June 2013.
Management Commentary, Risks, and Outlook
Management Response: CEO Sir Andrew Witty described the matter as "deeply disappointing" but emphasized GSK's commitment to China, where the company has operated for nearly a century. GSK has issued a public apology and pledged to continue investing in the country's healthcare reform.
Rectification Measures: GSK has implemented comprehensive changes to address the breach of governance, including:
- Fundamentally changing the salesforce incentive program by decoupling sales targets from compensation.
- Significantly reducing and altering engagement activities with healthcare professionals.
- Expanding processes for the review and monitoring of invoicing and payments.
Risks: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing the "Risk factors" section of the 2013 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the impact of the £297 million fine on the third-quarter financial results and cash flow statements.
- Review the upcoming third-quarter update for details on restructuring costs and charges.
- Assess the long-term operational impact of the decoupled sales incentive program in China.
- Monitor for any further regulatory actions or penalties from Chinese authorities.